Chris Moxham is the CEO of Transcripta Bio, a platform drug development biotechnology company which he joined as Chief Scientific Officer (CSO) in 2021 in its previous incarnation known as Rarebase. His career spans more than 25 years in drug discovery, particularly cutting-edge science and drug hunting in large pharma and biotech.

Before Transcripta, Moxham was CSO at Fulcrum Therapeutics, a clinical stage biotech focused on rare diseases, where he was responsible for the full range of drug discovery, translational science and early development activities including building and advancing the company’s preclinical portfolio through Phase 1 clinical trials. He was the scientific lead for Pociredir (FTX-6058), which is currently in phase 1 clinical testing for Sickle Cell Disease.

Moxham also spent 20 years at Eli Lilly and Co. where he helped bring over 10 molecules into the clinic across multiple therapeutic areas and across both small and large molecule modalities. Prior to leaving Eli Lilly in 2019, Moxham was Vice President of Quantitative Biology.

Moxham received his Bachelor of Science degree in biology from Cornell University and his PhD in molecular and cellular pharmacology from Stony Brook University.

Pharmaceutical, Biotechnology, Research & Exploration, Science, Science and Technology Professionals, Sickle Cell Disease, CEO, Chief Executive Officer (CEO), Business Founders, Artificial Intelligence, Startup, Biology, Molecular Biology, Gene Therapy